X4 Pharmaceuticals, Inc: Coastlands Capital LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Coastlands Capital LP amended its Schedule 13G filing on X4 Pharmaceuticals, Inc., updating its beneficial ownership stake with the SEC under accession number 0001104659-26-127412. The amendment signals a change in the institutional investor's position in the clinical-stage biopharmaceutical company. X4 Pharmaceuticals focuses on developing therapies for rare diseases and immune system disorders. Investors will watch for further 13G or 13D filings to gauge whether Coastlands' stake change reflects a broader shift in institutional sentiment toward the stock.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Coastlands Capital LP, X4 Pharmaceuticals, Inc.